In a similar manner, the inhibition of glutamine metabolism and antioxidant transcription factor NRF2 could also suppress the proliferation of residual breast cancer after HER2 inhibition and restore intracellular GSH metabolism (Fox et al., 2020). Here, ERBB2 is linked to breast carcinoma.